Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT).
August 06, 2024 | 3:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100